1. Home
  2. PAYC vs UTHR Comparison

PAYC vs UTHR Comparison

Compare PAYC & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Paycom Software Inc.

PAYC

Paycom Software Inc.

HOLD

Current Price

$165.63

Market Cap

8.9B

Sector

Technology

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$488.92

Market Cap

20.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAYC
UTHR
Founded
1998
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.9B
20.3B
IPO Year
2014
1999

Fundamental Metrics

Financial Performance
Metric
PAYC
UTHR
Price
$165.63
$488.92
Analyst Decision
Buy
Buy
Analyst Count
13
12
Target Price
$225.42
$495.08
AVG Volume (30 Days)
765.0K
424.3K
Earning Date
11-05-2025
10-29-2025
Dividend Yield
0.91%
N/A
EPS Growth
N/A
16.08
EPS
8.05
26.38
Revenue
$2,001,300,000.00
$3,128,400,000.00
Revenue This Year
$11.03
$13.64
Revenue Next Year
$8.85
$5.78
P/E Ratio
$20.59
$18.55
Revenue Growth
9.72
13.50
52 Week Low
$156.50
$266.98
52 Week High
$267.76
$492.62

Technical Indicators

Market Signals
Indicator
PAYC
UTHR
Relative Strength Index (RSI) 41.79 68.10
Support Level $159.49 $470.13
Resistance Level $164.54 $492.62
Average True Range (ATR) 3.89 10.72
MACD 1.93 -0.53
Stochastic Oscillator 68.49 89.55

Price Performance

Historical Comparison
PAYC
UTHR

About PAYC Paycom Software Inc.

Founded in 1998, Paycom is a human capital management software-as-a-service provider addressing customer requirements surrounding payroll, talent acquisition, talent management, HR management, as well as time and labor. The company primarily services midsize businesses within the United States, targeting businesses with 50-10,000 employees. The company primarily generates revenue through the sale of subscriptions providing access to its HCM platform. To a lesser extent, the company also generates revenue from implementation services provided to customers as well as interest income generated from customer funds. As of fiscal 2024, the company serviced slightly over 37,500 customers and stored data on over 7 million employees.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: